A practical reference on thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-25. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
== Literatur == M. L. Greenberg, T. Melby, P. Sista et al.: Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and 2 to 24 weeks. Abstract 141, 10th CROI 2003, Boston. J. Lalezari, C. Cohen, J. Eron, and the T20-205 study group: Forty eight week analysis of patients receiving T-20 as a component of multidrug salvage therapy. Abstract LbPp116, XIII Int AIDS Conf 2000, Durban, South Africa. J. Lalezari, E. DeJesus, D. Northfelt et al.: A week 48 assessment of a randomized, controlled, open-label phase II trial (T20-206) evaluating 3 doses of T-20 in PI-experienced, NNRTI-naïve patients infected with HIV-1. Abstract 418, 9th CROI 2002, Seattle, USA. A. Lazzarin, F. Queiroz-Telles, I. Frank et al.: TMC114 provides durable viral load suppression in treatment-experienced patients: POWER 1 and 2 combined week 48 analysis. TUAB0104, XVI IAC 2006, Toronto. J. Lu, P. Sista, N. Cammack, D. Kuritzkes et al.: Fitness of HIV-1 clinical isolates resistant to T-20 (enfuvirtide). In: Antiviral Therapy. 7, 2002, S. S56 S. Walmsley, K. Henry, C. Katlama et al.: Lack of influence of gp41 antibodies that cross-react with enfuvirtide on the efficacy and safety of enfuvirtide in TORO 1 and TORO 2 Phase III trials. Abstract 558, 10th CROI 2003, Boston. M. Harris, R. Joy, G. Larsen et al.: Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector). In: AIDS. Band 20, 2006, S. 719–723. PMID 16514302 C. B. Hicks, P. Cahn, D. A.
Cooper et al.: Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the RESIST studies: an analysis of combined data from two randomised open-label trials. In: The Lancet. Band 368, 2006, S. 466–475. PMID 16890833 J. M. Kilby, S. Hopkins, T. M. Venetta et al.: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. In: Nat Med. Band 4, 1998, S. 1302–1307. PMID 9809555 J. M. Kilby, J. P. Lalezari, J. J. Eron et al.: The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. In: AIDS Res Hum Retroviruses. Band 18, 2002, S. 685–693. PMID 12167274 J. P. Lalezari, K. Henry, M. O’Hearn et al.: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. In: N Engl J Med. Band 348, 2003, S. 2175–2185. PMID 12637625 J. Lalezari, J. Godrich, E. DeJesus et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/3 study in the US and Canada. Abstract 104LB, 14th CROI 2007, Los Angeles. A. Lazzarin, B. Clotet, D. Cooper et al.: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. In: N Engl J Med. Band 348, 2003, S. 2186–2195. PMID 12773645 G. Lehrman, I. B. Hogue, S.
Palmer et al.: Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. In: Lancet. Band 366, 2005, S. 549–555. PMID 16099290. T. Melby, P. Sista, R. DeMasi et al.: Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. In: AIDS Res Hum Retroviruses. Band 22, 2006, S. 375–385. Abstract: PMID 16706613 S. Menzo, A. Castagna, A. Monachetti et al.: Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment. In: New Microbiol. Band 27, 2004, S. 51–61. PMID 15646065 M. Mink, S. M. Mosier, S. Janumpalli et al.: Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. In: J Virol. Band 79, 2005, S. 12447–12454. PMID 16160172 J. Molto, L. Ruiz, M. Valle et al.: Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients. In: Antivir Ther. Band 11, 2006, S. 47–51. Abstract: PMID 16518959 M. Nelson, K. Arasteh, B. Clotet et al.: Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. In: J AIDS. Band 40, 2005, S. 404–412. PMID 16280694 M. Nelson, G. Fätkenheuer, I. Konourina et al.
Sources: de.wikipedia.org
Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia and North America: 24 week results. Abstract 104aLB, 14th CROI 2007, Los Angeles. V. Oldfield, G. M. Keating, G. Plosker: Enfuvirtide: A Review of its Use in the Management of HIV Infection. In: Drugs. Band 65, 2005, S. 1139–1160. PMID 15907147 F. Raffi, C. Katlama, M. Saag et al.: Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. In: Clin Infect Dis. Band 42, 2006, S. 870–877. PMID 16477567. H. Stocker, C. Kloft, N. Plock et al.: Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings. In: Antimicrob Agents Chemother. Band 50, 2006, S. 667–673. PMID 16436725 M. Thompson, E. DeJesus, G. Richmond et al.: Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjects. In: AIDS. Band 20, 2006, S. 397–404. PMID 16439873. B. Trottier, S. Walmsley, J. Reynes et al.: Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. In: JAIDS. Band 40, 2005, S. 413–421. PMID 16280695. M. Youle, S. Staszweski, B. Clotet et al.: Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations. In: HIV Clin Trials.
Sources: de.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
Dry lyophilized powder tolerates short ambient exposure during handling and shipping. Long-term room-temperature storage is not recommended because moisture uptake and slow degradation can occur over months. Storage at minus twenty degrees Celsius is the common practice for extended periods.